Fatty liver, also known as fatty liver disease (FLD), is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis (i.e. abnormal retention of lipids within a cell).
Inflammatory fatty liver disease (NASH, non alcoholic steatohepatitis ) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ) now show what ist behind this destructive behavior. I
A recently developed amino acid compound successfully treats nonalcoholic fatty liver disease in non-human primates -; bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests.
A new chip that holds different cell types in tiny, interconnected chambers could allow scientists to better understand the physiological and disease interactions between organs.
Recent research from the University of Jyväskylä contrasted the gut microbiota and gut-derived metabolites of healthy controls and fatty liver patients. The findings show that some microbial metabolites are linked to liver fat content.
A shot of a liver-produced hormone called FGF21 sobered up mice that had passed out from alcohol, allowing them to regain consciousness and coordination much faster than those that didn't receive this treatment, UT Southwestern researchers report in a new study.
The human immune system is incredibly versatile. Among its most skilled multitaskers are T cells, known for their role in everything from fighting infection to reining in inflammation to killing nascent tumors.
Jon Jacobs, a biochemist, has examined the blood of people suffering from diseases including Ebola, cancer, TB, hepatitis, diabetes, Lyme disease, brain damage, and influenza.
University of Virginia School of Medicine researchers have discovered a key trigger for non-alcoholic fatty liver disease, a mysterious condition that causes fat to build up in the liver for no clear reason.
Macrophages are immune system cells that control inflammation and tissue function in addition to being crucial in the early response to microbial infection. Since it aids in the repair of damaged tissue, inflammation is a natural physiological response.
There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases.
A significant genome-wide association study on the nonalcoholic fatty liver disease (NAFLD) has just been published in Nature Genetics by researchers from Amgen subsidiary deCODE Genetics.
A long-running debate in gastroenterology has been settled by WEHI researchers who have shown that prevalent liver diseases are not caused by inflammatory cell death as previously believed.
The immune system may attack the liver when fat builds up there. The chemical that triggers these responses has been discovered by Weill Cornell Medicine researchers in a recent study, and this information helps to explain the dynamics of liver damage that can accompany type 2 diabetes and obesity.
A multidisciplinary group of researchers at the University of California San Diego School of Medicine have advanced investigations into the genetic causes of NAFLD in children.
First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery.
Non-alcoholic fatty liver disease (NAFLD), commonly known as fatty liver disease, is a prevalent disease frequently seen in obese people. Having high fat content in the liver is detrimental as it is strongly associated with severe health problems like diabetes, high blood pressure, and liver cancer.
In a breakthrough discovery, scientists from The University of Texas Health Science Center at San Antonio today reported that inhibiting a liver enzyme in obese mice decreased the rodents' appetite, increased energy expenditure in adipose (fat) tissues and resulted in weight loss.
A new scientific review, published in Nutrients, highlights coffee's effects on digestion and the gut, and its impact on organs involved in digestion.
Professor Yuichi Oike and his group of researchers recently produced a peptide vaccine that mitigates conditions of dyslipidemia.
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver unrelated to alcohol abuse or other liver diseases.